Victoza and Ozempic share the same drug class, the same manufacturer, and a similar price tag — but in practice, they're very different medications. One requires a daily injection; the other is weekly. One has largely been superseded by the other in weight-loss conversations. And one is available through telehealth at a fraction of the brand-name cost.
If you're on Victoza and wondering whether to switch, or comparing options for the first time, this guide covers the clinical data that matters.
Quick Comparison
| Victoza | Ozempic | |
|---|---|---|
| Active ingredient | Liraglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA-approved for | Type 2 diabetes; CV risk reduction | Type 2 diabetes; CV risk reduction |
| FDA approved | 2010 | 2017 |
| Injection frequency | Once daily | Once weekly |
| Max dose | 1.8mg/day | 2.0mg/week |
| Avg. A1C reduction | ~1.0–1.5% | ~1.5–1.8% |
| Avg. weight loss (diabetes trials) | ~2–3 kg | ~4–6 kg |
| Brand list price | ~$850–$1,000/month | ~$850–$1,000/month |
| Compounded option? | Not available | Yes — widely available through telehealth |
| Weight loss FDA approval? | No (Saxenda has liraglutide at 3.0mg) | Yes — as Wegovy (2.4mg/week) |
What Each Medication Is
Victoza (Liraglutide)
Victoza is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved in 2010 for type 2 diabetes management. It was one of the first GLP-1 medications to achieve widespread clinical use and built a strong prescribing track record through the early 2010s.
Key characteristics:
- Administered as a subcutaneous injection once daily at any time of day
- Starting dose: 0.6mg/day for one week (GI acclimation), then titrated to 1.2mg/day
- Maximum dose: 1.8mg/day for additional glycemic benefit
- Also FDA-approved to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (based on the LEADER trial)
- A higher-dose version (3.0mg/day) is sold as Saxenda for chronic weight management
Victoza's half-life is approximately 13 hours — the reason it requires daily dosing. It was a major advance over older diabetes medications when it launched, but the GLP-1 class has since evolved substantially.
Ozempic (Semaglutide)
Ozempic is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved in 2017, seven years after Victoza. Semaglutide's molecular structure was modified from liraglutide to extend its half-life to approximately seven days, enabling once-weekly dosing.
Key characteristics:
- Administered as a subcutaneous injection once weekly, on any consistent day
- Titration: 0.25mg/week (4 weeks) → 0.5mg/week (4 weeks) → 1.0mg/week → 2.0mg/week
- Also FDA-approved to reduce cardiovascular events in adults with type 2 diabetes or established cardiovascular disease
- The same active ingredient at 2.4mg/week is sold as Wegovy, FDA-approved for chronic weight management
- Compounded semaglutide — the same active ingredient — is widely available through telehealth providers at $99–$450/month
The molecular modification that makes semaglutide weekly-dosed also makes it more potent at equivalent molar concentrations, which is reflected in the clinical trial data.
Efficacy: A1C Reduction and Weight Loss
Head-to-Head Data
The most direct comparison comes from the SUSTAIN 10 trial, which compared semaglutide 1.0mg weekly to liraglutide 1.2mg daily in patients with type 2 diabetes inadequately controlled on oral medications.
Results at 30 weeks:
| Outcome | Semaglutide 1.0mg/week | Liraglutide 1.2mg/day |
|---|---|---|
| A1C reduction | −1.5% | −1.0% |
| Weight loss | −5.8 kg | −2.2 kg |
| Patients reaching A1C <7% | 79% | 62% |
Semaglutide significantly outperformed liraglutide on both glycemic control and weight reduction, with statistically significant differences across all primary endpoints.
The SUSTAIN 7 trial compared semaglutide to dulaglutide (Trulicity) and produced comparable or superior results for semaglutide, complementing the body of evidence from SUSTAIN 10. See our Trulicity vs Ozempic comparison for more on the dulaglutide data.
Weight Loss: The Bigger Picture
The weight loss gap between liraglutide and semaglutide widens at obesity-indicated doses:
- Saxenda (liraglutide 3.0mg) — the SCALE trial found average weight loss of ~8% of body weight at 56 weeks
- Wegovy (semaglutide 2.4mg) — the STEP trials found average weight loss of ~15% of body weight at 68 weeks
Both are active ingredients from the same manufacturer, both GLP-1 agonists, but semaglutide at its obesity dose achieves roughly twice the weight loss. This difference is one reason Victoza is rarely prescribed in 2026 for patients whose primary goal involves weight management.
A1C Reduction Summary
| Medication | Dose | Avg. A1C Reduction |
|---|---|---|
| Victoza | 1.2mg/day | ~1.0% |
| Victoza | 1.8mg/day | ~1.2–1.5% |
| Ozempic | 0.5mg/week | ~1.4% |
| Ozempic | 1.0mg/week | ~1.6–1.8% |
| Ozempic | 2.0mg/week | ~1.8%+ |
For patients whose primary need is A1C reduction, both medications are effective — but semaglutide consistently achieves better glycemic control at comparable doses.
Side Effects
Both Victoza and Ozempic share the core GLP-1 side effect profile. The mechanism is the same, so the types of side effects are predictable.
Common Side Effects (Both Medications)
- Nausea — most common, especially when starting or increasing dose
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- Injection site reactions — redness, itching, or minor bruising
Most gastrointestinal effects are dose-dependent and transient. They typically peak during the titration phase and resolve as the body adjusts.
Differences in Tolerability
The daily vs. weekly dosing structure does create meaningful differences in how side effects are experienced:
- Victoza's daily dosing means GI symptoms can be more persistent early on, since patients experience a daily dose peak
- Ozempic's weekly dosing means patients experience one weekly peak; some patients find this easier to tolerate, though others report a "rough day" each week during the first month
Neither medication has been shown to cause significantly more discontinuation due to side effects than the other in head-to-head trials. Individual response varies considerably.
Serious Risks (Both Medications)
Both Victoza and Ozempic carry identical boxed warnings and share the same serious risk profile:
- Thyroid C-cell tumors — seen in rodent studies; risk in humans not established, but both carry a warning to avoid use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome
- Pancreatitis — rare; discontinue if acute symptoms develop
- Gallbladder disease — increased risk, particularly with rapid weight loss
- Diabetic retinopathy — semaglutide-specific signal noted in the SUSTAIN-6 trial; patients with pre-existing retinopathy should discuss monitoring with their provider
The thyroid warning applies to both medications. This warning relates specifically to MTC — not to common thyroid conditions like hypothyroidism or Hashimoto's disease.
Cost and Access
Brand-Name Pricing
Both Victoza and Ozempic have comparable brand-name list prices without insurance:
- Victoza: ~$850–$1,000/month (depending on dose)
- Ozempic: ~$850–$1,000/month
GoodRx and manufacturer savings cards may reduce out-of-pocket costs for commercially insured patients not on federal programs.
The Compounded Semaglutide Advantage
Here the comparison shifts decisively. Compounded semaglutide — the active ingredient in Ozempic and Wegovy — is available through licensed telehealth providers in the $99–$450/month range. No comparable compounded liraglutide option is widely available in the United States.
| Provider | Monthly Cost (Semaglutide) | Notes |
|---|---|---|
| Belle Health | ~$119/mo | Flat rate at all doses |
| Henry Meds | ~$149/mo | No consultation fee |
| Ro | ~$149/mo | Includes video consultation |
| Found | ~$159/mo | Includes coaching |
| Hims | ~$199/mo | Compounded semaglutide |
If cost is a significant factor, accessing semaglutide through a telehealth provider is substantially more affordable than Victoza at any price point. Use our provider comparison tool to find options in your state.
Telehealth Access
Semaglutide is the dominant GLP-1 medication in telehealth because of the compounded option, its obesity indication, and patient demand. Telehealth platforms built around GLP-1 medications almost universally offer semaglutide — and many do not offer liraglutide at all.
If you're looking to switch from Victoza to a lower-cost weekly option, the telehealth route for compounded semaglutide is the most practical path.
Should You Switch from Victoza to Ozempic?
For patients currently on Victoza, the clinical and practical case for switching to semaglutide has strengthened considerably since both drugs were launched:
Switch strongly supported when:
- Weight loss is a goal alongside or instead of diabetes management
- Daily injections are inconvenient or you're having adherence issues
- Cost is a barrier and you want to explore compounded semaglutide through telehealth
- You want the stronger A1C reduction data and broader cardiovascular outcome evidence
Staying on Victoza may be appropriate when:
- You're well-controlled on liraglutide with no desire to change
- Your insurance covers Victoza at a low copay and semaglutide requires step therapy
- You have a clinical reason identified by your prescriber (e.g., tolerance differences in specific patients)
- You've previously tried semaglutide and did not tolerate it as well
When switching, your prescriber will typically start semaglutide at the 0.25mg/week introductory dose and titrate up, regardless of your current Victoza dose.
How to Choose
For glycemic control alone: Both are effective. If you're well-controlled on Victoza, there is no clinical urgency to switch. If you're looking to optimize, semaglutide has better A1C outcomes at comparable doses.
For weight loss: Semaglutide at therapeutic doses consistently outperforms liraglutide. If weight management is a primary goal, semaglutide (Ozempic/Wegovy) is the supported option.
For convenience: Once-weekly semaglutide is meaningfully easier to adhere to than once-daily liraglutide for most patients.
For cost: Compounded semaglutide through telehealth offers no equivalent on the liraglutide side. If you're paying out of pocket or navigating insurance barriers, semaglutide is the more accessible option.
Browse telehealth providers offering semaglutide through our provider comparison page.
Frequently Asked Questions
Is Victoza or Ozempic better for weight loss?
Ozempic (semaglutide) produces substantially more weight loss than Victoza (liraglutide). The SUSTAIN 10 head-to-head trial showed semaglutide 1.0mg/week averaged −5.8 kg weight loss versus −2.2 kg for liraglutide 1.2mg/day. At the obesity-indicated dose (semaglutide 2.4mg via Wegovy), average weight loss exceeds 15% of body weight in clinical trials — roughly double the weight loss seen with Saxenda (high-dose liraglutide). For weight management, semaglutide is the clinically supported choice.
Can I switch from Victoza to Ozempic?
Yes — switching is common and generally well-tolerated. Your prescriber will typically restart at semaglutide's initiation dose (0.25mg/week for four weeks) and titrate up, regardless of your current Victoza dose. The once-weekly schedule is a logistical improvement for most patients. Discuss the switch with your prescriber to confirm your diabetes or weight management plan is covered during the transition.
What is the cost difference between Victoza and Ozempic?
Both have similar brand-name prices (~$850–$1,000/month). The decisive difference is compounded semaglutide: Ozempic's active ingredient is available through telehealth providers for $99–$450/month. No comparable compounded liraglutide option is widely available. For patients without insurance coverage or seeking cost-effective access, semaglutide through telehealth is meaningfully more affordable.
Does Victoza have any advantages over Ozempic?
For most patients in 2026, semaglutide's once-weekly dosing, stronger efficacy data, and telehealth accessibility through compounded options make it the preferred choice. Victoza may be appropriate if you're stabilized on liraglutide, your insurance strongly prefers it, or your prescriber has a clinical reason for the preference. Some patients also tolerate daily liraglutide better than weekly semaglutide — individual response varies. The right choice depends on your specific health goals and circumstances, which is best evaluated with your prescriber.